Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 2Leukemia, Myeloid, Acute 2Leukemia 2Skin Neoplasms 1Recurrence 1

Interventions

pembrolizumab 3Ipilimumab 3Educational Status 3Biopsy 3Optical Imaging 2Nivolumab 2Early Intervention, Educational 2Ascorbic Acid 2methyl 5-aminolevulinate 1lavender oil 1four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate) 1fludarabine phosphate 1fludarabine 1aldesleukin 1Zinc 1Water 1Trimethoprim, Sulfamethoxazole Drug Combination 1Tomography, Optical Coherence 1Toll-Like Receptor 1 1Tea 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1Spermine Synthase 1Specimen Handling 1Semaxinib 1Second Harmonic Generation Microscopy 1Risk Factors 1Resistance Training 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Skin Neoplasms × Interleukin-2 × Clear all
NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
13 enrolled 10 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡